MDL 12330A hydrochloride (Synonyms: RMI 12330A) |
| Catalog No.GC12075 |
adenylate cyclase inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 40297-09-4
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
IC50: 1.5 X 10-5 M for histamine-stimulated adenylate cyclase [1].
RMI 12330 A is N,-(cis-2-phenylcyclopentyl) azacyclotridecan-2-imine hydrochloride, which has been reported to inhibit choleratoxin-induced intestinal hypersecretion, presumably via an inhibition of mucosal adenylate cyclase.
In vitro: RMI 12330 A at the concentration of ranging from 10 uM to 5 mM the can effectively inhibit the adenylate cyclase activity of a rat liver plasma membrane preparation. RMI 12330 A does not apply its competition on the catalytic site of the enzyme to perform its inhibitory action. The inhibition activity of RMI 12330 A upon adenylate cyclase was due to an irreversible binding with the plasma membranes [2].
Ex vivo: In the isolated work-performing heart of the guinea-pig, RMI 12330A depressed all cardiac functions with the IC50 of 1.1 X 10-6 M, including contractile force, dP/dt, dF/dt, pressures developed, stroke work and work performance. The positive inotropic response to increasing heart rate (staircase) and left atrial pressure rose became negative. Ouabain, isoprenaline and histamine, no longer had positive inotropic effects. After its depression by RMI 12330A, the cardiac function can be completely restored by increasing the perfusate calcium concentration from 2.5 mm to 4.5 and 6.5 mm [1].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Grupp G, Grupp IL, Johnson CL, Matlib MA, Rouslin W, Schwartz A, Wallick ET, Wang T, Wisler P. Effects of RMI 12330A, a new inhibitor of adenylate cyclase on myocardial function and subcellular activity. Br J Pharmacol. 1980 Nov;70(3):429-42.
[2] Guellaen G, Mahu JL, Mavier P, Berthelot P, Hanoune J. RMI 12330 A, an inhibitor of adenylate cyclase in rat liver. Biochim Biophys Acta. 1977 Oct 13;484(2):465-75.
| Cas No. | 40297-09-4 | SDF | |
| Synonyms | RMI 12330A | ||
| Chemical Name | (E)-N-((1R,2R)-2-phenylcyclopentyl)azacyclotridec-1-en-2-amine hydrochloride | ||
| Canonical SMILES | [C@@H](CCC1)(C2=CC=CC=C2)[C@@H]1N/C3=N/CCCCCCCCCCC3.Cl | ||
| Formula | C23H36N2.HCl | M.Wt | 377.01 |
| Solubility | 1mg/ml in DMF, 1mg/ml in Ethanol | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6524 mL | 13.2622 mL | 26.5245 mL |
| 5 mM | 0.5305 mL | 2.6524 mL | 5.3049 mL |
| 10 mM | 0.2652 mL | 1.3262 mL | 2.6524 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *